DCOY
Decoy Therapeutics Inc.
Price Chart
Latest Quote
$6.07
+0.12 (+2.02%)
Current Price
| Previous Close | $5.95 |
| Open | $6.09 |
| Day High | $6.14 |
| Day Low | $6.07 |
| Volume | 5,830 |
Stock Information
| Shares Outstanding | 532K |
| Cash Equivalents | $7.82M |
| Net Income | $-13.03M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.23M |
| P/E Ratio | 0.06 |
| EPS (TTM) | $105.57 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-4.59M |
| Income | $-13.03M |
| Book/sh | $7.29 |
| Cash/sh | $14.70 |
| Employees | 11 |
Financial Ratios
| Quick Ratio | 1.72 |
| Current Ratio | 1.84 |
Returns & Margins
| ROA | -54.13% |
| ROE | -661.73% |
Ownership
| Insider Ownership | 0.58% |
| Institutional Ownership | 11.48% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.31 |
| P/B | 0.83 |
Analyst Data
| Recommendation | none |
| Target Price | $30.00 |
Technical Indicators
| SMA20 | $6.89 |
| SMA50 | $6.11 |
| SMA200 | $18.12 |
| RSI | 20.98 |
| ATR | 0.9059 |
| Shares Float | 528K |
| Short Float | 1.73% |
| Short Ratio | 0.82 |
| Volatility | 0.58 |
| Rel Volume | 0.37 |
Performance History
| Week | +2.88% |
| Month | +14.53% |
| Quarter | -24.03% |
| 6 Months | -29.45% |
| YTD | -22.42% |
| Year | -96.79% |
| 3 Years | -99.76% |
| 5 Years | -99.99% |
| 10 Years | -100.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $6.07 | 6,100 |
| 2026-06-17 | $5.95 | 18,000 |
| 2026-06-16 | $5.88 | 4,300 |
| 2026-06-15 | $6.10 | 4,000 |
| 2026-06-12 | $6.01 | 12,000 |
| 2026-06-11 | $5.90 | 7,700 |
| 2026-06-10 | $5.59 | 21,500 |
| 2026-06-09 | $5.51 | 17,500 |
| 2026-06-08 | $6.25 | 10,900 |
| 2026-06-05 | $6.61 | 22,000 |
| 2026-06-04 | $6.71 | 25,800 |
| 2026-06-03 | $7.97 | 24,700 |
| 2026-06-02 | $8.61 | 21,100 |
| 2026-06-01 | $8.36 | 40,100 |
| 2026-05-29 | $8.92 | 15,600 |
| 2026-05-28 | $7.91 | 10,900 |
| 2026-05-27 | $8.05 | 9,100 |
| 2026-05-26 | $7.63 | 24,700 |
| 2026-05-22 | $7.30 | 10,700 |
| 2026-05-21 | $6.43 | 27,500 |
| 2026-05-20 | $5.56 | 3,800 |
| 2026-05-19 | $5.30 | 20,500 |
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
đ° Latest News
No news articles available at the moment. Check back later for updates on DCOY.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $12,613,952 | $5,734,316 | $12,894,944 | $22,975,231 |
| Net Non Operating Interest Income Expense | $95,472 | $158,539 | $352,251 | $218,730 |
| Operating Expense | $12,613,952 | $5,734,316 | $12,894,944 | $22,975,231 |
| General And Administrative Expense | $3,727,816 | $4,964,289 | $5,721,197 | $7,138,403 |
| Other Income Expense | - | - | - | $-8,851,455 |
| Other Operating Expenses | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-12,518,480 | $-5,575,777 | $-12,542,693 | $-31,607,956 |
| Net Interest Income | $95,472 | $158,539 | $352,251 | $218,730 |
| Interest Income | $95,472 | $158,539 | $352,251 | $218,730 |
| Normalized Income | $-12,518,480 | $-5,575,777 | $-12,542,693 | $-22,756,501 |
| Net Income From Continuing And Discontinued Operation | $-12,518,480 | $-5,575,777 | $-12,542,693 | $-31,607,956 |
| Total Operating Income As Reported | $-12,613,952 | $-5,734,316 | - | $-31,841,140 |
| Net Income Common Stockholders | $-12,518,480 | $-5,575,777 | $-12,542,693 | $-31,607,956 |
| Net Income | $-12,518,480 | $-5,575,777 | $-12,542,693 | $-31,607,956 |
| Net Income Including Noncontrolling Interests | $-12,518,480 | $-5,575,777 | $-12,542,693 | $-31,607,956 |
| Net Income Continuous Operations | $-12,518,480 | $-5,575,777 | $-12,542,693 | $-31,607,956 |
| Pretax Income | $-12,518,480 | $-5,575,777 | $-12,542,693 | $-31,607,956 |
| Interest Income Non Operating | $95,472 | $158,539 | $352,251 | $218,730 |
| Operating Income | $-12,613,952 | $-5,734,316 | $-12,894,944 | $-22,975,231 |
| Special Income Charges | - | - | $0 | $-8,865,909 |
| Per Share | ||||
| Diluted EPS | $-129.10 | $-1043.10 | $-5533.20 | $-21427.20 |
| Basic EPS | $-129.10 | $-1043.10 | $-5533.20 | $-21427.20 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-12,606,801 | $-5,729,892 | $-12,884,893 | $-14,117,099 |
| Reconciled Depreciation | $7,151 | $4,424 | $10,051 | $6,677 |
| EBITDA (Bullshit earnings) | $-12,606,801 | $-5,729,892 | $-12,884,893 | $-22,968,554 |
| EBIT | $-12,613,952 | $-5,734,316 | $-12,894,944 | $-22,975,231 |
| Diluted Average Shares | $96,966 | $5,345 | $2,267 | $1,475 |
| Basic Average Shares | $96,966 | $5,345 | $2,267 | $1,475 |
| Diluted NI Availto Com Stockholders | $-12,518,480 | $-5,575,777 | $-12,542,693 | $-31,607,956 |
| Research And Development | $8,886,136 | $770,027 | $7,173,747 | $15,836,828 |
| Selling General And Administration | $3,727,816 | $4,964,289 | $5,721,197 | $7,138,403 |
| Other Gand A | $3,727,816 | $4,964,289 | $5,721,197 | $7,138,403 |
| Total Unusual Items | - | - | $0 | $-8,851,455 |
| Total Unusual Items Excluding Goodwill | - | - | $0 | $-8,851,455 |
| Impairment Of Capital Assets | - | - | $0 | $8,865,909 |
| Gain On Sale Of Security | - | - | - | $14,454 |
| Otherunder Preferred Stock Dividend | - | - | - | - |
Fetched: 2026-06-20
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $5,888,969 | $1,511,695 | $5,287,282 | $10,384,608 |
| Total Assets | $11,056,707 | $3,022,974 | $6,586,523 | $14,650,799 |
| Total Non Current Assets | $71,547 | $35,412 | $66,850 | $130,501 |
| Other Non Current Assets | $30,988 | $35,412 | $66,850 | $130,501 |
| Current Assets | $10,985,160 | $2,987,562 | $6,519,673 | $14,520,298 |
| Other Current Assets | $275,223 | $43,669 | $151,268 | $792,188 |
| Current Deferred Assets | $0 | $221,580 | $0 | - |
| Prepaid Assets | $0 | $287,785 | $468,495 | $11,185 |
| Cash Cash Equivalents And Short Term Investments | $10,709,937 | $2,434,528 | $5,899,910 | $12,106,435 |
| Cash And Cash Equivalents | $10,709,937 | $2,434,528 | $5,899,910 | $12,106,435 |
| Receivables | - | - | $0 | $1,610,490 |
| Goodwill And Other Intangible Assets | - | - | - | $0 |
| Other Receivables | - | - | - | $1,610,490 |
| Non Current Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | - | $221,866 | $289,643 | - |
| Current Debt And Capital Lease Obligation | - | $221,866 | $289,643 | - |
| Current Debt | - | $221,866 | $289,643 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,167,738 | $1,511,279 | $1,299,241 | $4,266,191 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 | $0 |
| Current Liabilities | $5,167,738 | $1,511,279 | $1,299,241 | $4,266,191 |
| Other Current Liabilities | $2,306 | - | - | - |
| Current Deferred Liabilities | $3,225,581 | $0 | - | - |
| Current Notes Payable | $0 | $221,866 | $289,643 | $0 |
| Payables And Accrued Expenses | $1,939,851 | $1,289,413 | $1,009,598 | $4,266,191 |
| Payables | $1,080,409 | $936,994 | $602,853 | $2,858,330 |
| Accounts Payable | $940,586 | $936,994 | $602,853 | $2,858,330 |
| Equity | ||||
| Common Stock Equity | $5,888,969 | $1,511,695 | $5,287,282 | $10,384,608 |
| Total Equity Gross Minority Interest | $5,888,969 | $1,511,695 | $5,287,282 | $10,384,608 |
| Stockholders Equity | $5,888,969 | $1,511,695 | $5,287,282 | $10,384,608 |
| Retained Earnings | $-94,442,098 | $-81,923,618 | $-76,347,841 | $-63,805,148 |
| Other | ||||
| Ordinary Shares Number | $531,967 | $8,006 | $2,735 | $1,566 |
| Share Issued | $531,967 | $8,006 | $2,735 | $1,566 |
| Tangible Book Value | $5,888,969 | $1,511,695 | $5,287,282 | $10,384,608 |
| Invested Capital | $5,888,969 | $1,733,561 | $5,576,925 | $10,384,608 |
| Working Capital | $5,817,422 | $1,476,283 | $5,220,432 | $10,254,107 |
| Total Capitalization | $5,888,969 | $1,511,695 | $5,287,282 | $10,384,608 |
| Additional Paid In Capital | $100,331,014 | $83,435,312 | $81,635,074 | $74,189,531 |
| Capital Stock | $53 | $1 | $49 | $225 |
| Common Stock | $53 | $1 | $49 | $225 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Current Deferred Revenue | $3,225,581 | $0 | - | - |
| Current Accrued Expenses | $859,442 | $352,419 | $406,745 | $1,407,861 |
| Dueto Related Parties Current | $139,823 | $0 | - | - |
| Net PPE | $40,559 | $0 | - | - |
| Treasury Shares Number | - | - | $0 | - |
| Goodwill | - | - | - | $0 |
Fetched: 2026-06-20
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-5,404,188 | $-4,525,337 | $-12,846,137 | $-19,095,321 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,827,188 | $-4,525,337 | $-12,846,137 | $-17,595,321 |
| Cash Flow From Continuing Operating Activities | $-4,827,188 | $-4,525,337 | $-12,846,137 | $-17,595,321 |
| Operating Gains Losses | $-6,540 | - | - | $-14,454 |
| Investing Activities | ||||
| Capital Expenditure | $-577,000 | - | - | $-1,500,000 |
| Investing Cash Flow | $764,735 | $0 | $0 | $-1,500,000 |
| Cash Flow From Continuing Investing Activities | $764,735 | $0 | $0 | $-1,500,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $12,559,728 | $1,526,460 | $6,920,529 | $1,987,376 |
| Financing Cash Flow | $12,337,862 | $1,059,955 | $6,639,612 | $1,987,376 |
| Cash Flow From Continuing Financing Activities | $12,337,862 | $1,059,955 | $6,639,612 | $1,987,376 |
| Net Common Stock Issuance | $12,559,728 | $1,526,460 | $6,920,529 | $1,987,376 |
| Common Stock Issuance | $12,559,728 | $1,526,460 | $6,920,529 | $1,987,376 |
| Other | ||||
| Repayment Of Debt | $-221,866 | $-466,505 | $-280,917 | $0 |
| Interest Paid Supplemental Data | $5,800 | $10,643 | $14,754 | $0 |
| End Cash Position | $10,709,937 | $2,434,528 | $5,899,910 | $12,106,435 |
| Beginning Cash Position | $2,434,528 | $5,899,910 | $12,106,435 | $29,214,380 |
| Changes In Cash | $8,275,409 | $-3,465,382 | $-6,206,525 | $-17,107,945 |
| Net Issuance Payments Of Debt | $-221,866 | $-466,505 | $-280,917 | $0 |
| Net Short Term Debt Issuance | $-221,866 | $-466,505 | $-280,917 | $0 |
| Short Term Debt Payments | $-221,866 | $-466,505 | $-280,917 | $0 |
| Net Business Purchase And Sale | $1,341,735 | $0 | - | - |
| Sale Of Business | $1,341,735 | $0 | - | - |
| Net PPE Purchase And Sale | $-577,000 | $0 | - | - |
| Purchase Of PPE | $-577,000 | $0 | - | - |
| Change In Working Capital | $-1,046,343 | $772,286 | $-968,333 | $2,369,800 |
| Change In Payables And Accrued Expense | $-1,465,971 | $279,815 | $-3,256,593 | $2,167,262 |
| Change In Accrued Expense | $-298,903 | $-54,326 | $-1,001,116 | $854,527 |
| Change In Payable | $-1,167,068 | $334,141 | $-2,255,477 | $1,312,735 |
| Change In Account Payable | $-1,167,068 | $334,141 | $-2,255,477 | $1,312,735 |
| Change In Prepaid Assets | $419,628 | $492,471 | $807,770 | $202,538 |
| Other Non Cash Items | $8,517,966 | - | - | $1,987,900 |
| Stock Based Compensation | $219,058 | $273,730 | $524,838 | $796,803 |
| Depreciation Amortization Depletion | $7,151 | $4,424 | $10,051 | $6,677 |
| Depreciation And Amortization | $7,151 | $4,424 | $10,051 | $6,677 |
| Depreciation | $7,151 | $4,424 | $10,051 | $6,677 |
| Gain Loss On Investment Securities | $-6,540 | - | - | $-14,454 |
| Net Income From Continuing Operations | $-12,518,480 | $-5,575,777 | $-12,542,693 | $-31,607,956 |
| Change In Receivables | - | $0 | $1,480,490 | $0 |
| Asset Impairment Charge | - | $0 | $130,000 | $8,865,909 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-1,500,000 |
| Purchase Of Intangibles | - | - | $0 | $-1,500,000 |
| Proceeds From Stock Option Exercised | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | - |
| Long Term Debt Payments | - | - | - | - |
Fetched: 2026-06-20